International Cancer Research Conference
March 24-26, 2025 | Singapore
Cancer Neoantigens
Cancer neoantigens are novel peptides presented by cancer cells that arise from tumor-specific mutations. Unlike normal cellular proteins, these neoantigens are recognized as foreign by the immune system, making them promising targets for cancer immunotherapy. Neoantigen-based therapies, such as personalized cancer vaccines and adoptive T-cell transfer, aim to harness the body’s immune response to selectively attack tumor cells while sparing healthy tissue. Recent advances in genomics and bioinformatics have accelerated the identification and validation of neoantigens, paving the way for highly individualized treatments. These therapies hold potential for improved efficacy and reduced toxicity compared to traditional cancer treatments, marking a significant advancement in personalized oncology.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Jianhua Luo
University of Pittsburgh, United States
Kaushala Prasad Mishra
Asian Association for Radiation Research (AARR), India
Ibrahim El Bayoumy
Consultant of public health-Ministry of Health, Kuwait
Özlem Terzi
Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Turkey
Andrea González Báez
Autonomous University of Nuevo Leon, MexicoSubmit your abstract Today
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title :
Jianhua Luo, University of Pittsburgh, United States
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Principles of oral rehabilitation in H&N cancer patients
Pietro Salvatori, Independent H&N Surgeon, Italy
Title :
Marika Crohns, Impactful Innovations Management Consultants LLC, United Arab Emirates